Eli Lilly to sign $2 billion AI drug discovery deal

Eli Lilly is reportedly signing a $2 billion agreement with Hong Kong-based Insilico Medicine. The deal grants Lilly rights to sell a new GLP-1 diabetes drug.

Xurve View
洞察:

Eli Lilly and Company is reportedly nearing a $2 billion agreement with Insilico Medicine, a biotechnology firm specializing in the use of artificial intelligence for pharmaceutical discovery. According to a report from the Financial Times, the deal underscores a significant investment in AI-driven healthcare solutions.

An aerial perspective captures the Eli Lilly corporate logo at its facility in San Diego, California, taken in late 2025. REUTERS/Mike Blake